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Objective: Comorbidities are known to increase endometrial cancer risk, but the separate and 
combined impact of these risk factors on endometrial cancer survival remains unclear. This study 
aimed to determine the associations between metabolic syndrome and its components with 
disease-free survival, overall survival, endometrial cancer-specific survival and recurrence 
among endometrial cancer survivors. Methods: Cases from a population-based case-control 
study who were diagnosed with primary endometrial cancer between 2002 and 2006 in Alberta, 
Canada were followed until death or March 20, 2019. Baseline in-person interviews, direct 
anthropometric measurements and fasting blood samples were used to assess metabolic 
syndrome (presence of ≥3 of the following: waist circumference ≥ 88 cm, fasting blood glucose 
≥100 mg/dL, triglycerides ≥150 mg/dL, high-density lipoprotein cholesterol <50 mg/dL and self-
reported hypertension). Cox proportional hazards regression and Fine and Gray competing risk 
models were used to estimate multivariate-adjusted hazard ratios (95% CI) for these associations. 
Results: Among 540 endometrial cancer survivors, 325 had metabolic syndrome at diagnosis 
and 132 had a recurrence and/or died during the median 14.2 years of follow-up (range: 0.3–
16.5 years). In multivariable analyses, being diagnosed with metabolic syndrome (HR = 1.98, 
95% CI = 1.07–3.67) and having an elevated waist circumference (≥88 cm; HR = 2.12, 95% 
CI = 1.18–3.80; HRper 5 cm = 1.21, 95% CI = 1.07–1.36) were associated with worse overall 
survival. Additionally, increasing waist circumference (per 5 cm) was also associated worse with 
disease-free survival (HRper 5 cm = 1.11, 95% CI = 1.00–1.24). Conclusion: The metabolic 
syndrome, in particular central adiposity, were associated with worse overall and disease-free 
survival in endometrial cancer survivors. 
 






Endometrial cancer is the sixth most frequently diagnosed cancer among women worldwide [1]. 
In 2018, the International Agency for Research on Cancer (IARC) estimated that 382,069 new 
cases of endometrial cancer and 89,929 endometrial cancer-specific deaths occurred globally [1] 
with the highest rates occurring in North America and Central and Eastern Europe [1,2]. 
Between 2005 and 2015, uterine cancer mortality rates increased 2.0% annually in Canada and 
1.9% annually between 2011 and 2015 in the USA, making endometrial cancer one of the few 
cancer types with both increasing incidence and mortality rates [3,4]. 
 
Obesity and diabetes have been previously identified as major risk factors for endometrial 
cancer, whereas physical activity is thought to reduce endometrial cancer risk [2,5,6]. These risk 
factors may also be associated with endometrial cancer recurrence and mortality [7,8,9]. 
Specifically, obesity is an established risk factor for endometrial cancer survival, with 
convincing biological plausibility through metabolic disruptions, hormonal and growth factor 
imbalances, unopposed estrogens released by adipose tissue [10] and chronic inflammation that 
prompts tumor growth [2,10,11,12]. Furthermore, among cancer survivors, obesity has been 
associated with reduced responses to standard treatments, higher rates of metastatic disease and 
poorer prognoses compared to normal weight individuals [12]. Diabetes and hypertension may 
also increase cancer-specific mortality and all-cause mortality in this population [8,9,13,14,15]. 
However, the combined impact of these comorbidities on endometrial cancer survival outcomes 
remains unclear. 
 
Metabolic syndrome is defined as the clustering of cardiovascular and metabolic disease risk 
factors including central adiposity, hypertension, hyperglycemia, elevated triglycerides and low 
high-density lipoprotein (HDL) cholesterol [16]. Women with metabolic syndrome are estimated 
to have a roughly two-fold elevation in endometrial cancer risk [5,17,18,19,20,21] compared to 
those without. Despite biological plausibility that metabolic syndrome may also be associated 
with endometrial cancer recurrence and survival [10,22], limited information on survival 
outcomes currently exists. Therefore, the objective of the current study was to determine the 
associations between metabolic syndrome and its components, defined by harmonized criteria 
[16] with disease-free survival, overall survival, endometrial cancer-specific survival and 




2.1. Study design 
 
The Alberta Endometrial Cancer Cohort Study is a follow-up of women diagnosed with 
histologically confirmed, invasive, primary endometrial cancer between 2002 and 2006 who 
participated in a population-based case-control study in Alberta, Canada [23]. Full details of the 
case-control study have been previously reported [20,23]. Briefly, 549 (61.0%) of cases 
identified through the Alberta Cancer Registry who were residents of Alberta, English speaking, 
between 30 and 80 years of age, able to complete an interview and diet history questionnaire, and 
had no prior history of cancer except non-melanoma skin cancer, were included. Nine 
participants were excluded from this analysis due to unsatisfactory baseline interviews (n = 7), 
cancer misclassification (n = 1) and being diagnosed with an ineligible endometrial cancer sub-
type (neuroendocrine endometrial cancer; n = 1). The remaining 540 participants (60.0%) were 
included in this study. Ethical approval for the study was obtained from the Alberta Cancer 
Board, the Conjoint Health Research Ethics Board (University of Calgary) and the Health 
Research Ethics Board (University of Alberta). All participants provided informed, written 
consent. 
 
2.2. Data collection 
 
Participant's demographic information, menstrual and reproductive history, hormone use history, 
medical history, medication use information, family history of cancer, and lifetime smoking 
habits were collected via an interviewer-administered questionnaire following endometrial 
cancer diagnosis (mean 22 ± 11.5 weeks) [23]. Lifetime alcohol consumption and lifetime 
physical activity participation were measured with the Canadian Diet Health Questionnaire-I and 
the Lifetime Total Physical Activity Questionnaire (LTPAQ), respectively [24,25]. At the time 
of the interviews, standardized anthropometric measurements including the participant's height, 
weight and waist circumferences were taken in triplicate and the average was recorded as the 
final measurement [23]. Participants fasted for at least eight hours before blood samples were 
collected either pre-hysterectomy or four-six weeks post-hysterectomy if blood could not be 
drawn pre-surgery (pre-surgical n = 235; post-surgical n = 286). Blood samples were processed 
into blood fractions (serum, plasma, red blood cells, and buffy coat), frozen at −80 °C within 
24 h of collection and stored in biorepository at the Tom Baker Cancer Centre, Calgary, Alberta 
[26]. 
 
2.3. Follow-up and outcome ascertainment 
 
Clinical information including date of diagnosis, cancer histology and stage, primary and 
adjuvant treatment(s) received, cancer recurrence and occurrence of a new primary cancer 
diagnosis were abstracted from medical charts by the Alberta Cancer Registry trained Health 
Record Technicians. Overall stage (tumor, lymph node, metastasis (TNM)) was coded according 
to the American Joint Committee on Cancer guidelines [27]. Women with incomplete overall 
cancer TNM stage (n = 8) were coded based on available lymph node inclusion and metastatic 
information. Cancer grade (International Federation of Gynecology and Obstetrics) and tumor 
histology (endometrioid, mixed cell, serous, clear cell, mucinous adenocarcinoma, 
carcinosarcoma, adenosarcoma and other) were additionally available via tissue samples, as 
previously described [26]. Vital status and underlying cause of death data were provided by Vital 
Statistics Alberta and Statistics Canada, respectively. Vital status information from participants 
who died in provinces other than Alberta were obtained from data linkages between provincial 
cancer registries. 
 
For the purpose of this analysis, cancer recurrence was considered as any primary site recurrence 
or progression, lymph node recurrence or metastasis of the primary cancer noted in the medical 
record. Deaths that were attributable to endometrial or uterine (NOS) cancer were categorized as 
endometrial cancer-specific deaths. Survival time was calculated as the time from the initial 
diagnosis of endometrial cancer until death or March 20, 2019, whichever occurred first. 
Disease-free survival was defined as the time from diagnosis to the first recurrence or death from 
any cause, while overall survival was the time from diagnosis until the time of death from any 
cause. 
 
2.4. Statistical analysis 
 
Metabolic syndrome was categorized with the harmonized definition using country- and sex-
specific waist circumference criteria [16]. Participants with three or more of the following risk 
factors were classified as having metabolic syndrome: waist circumference ≥ 88 cm, fasting 
blood glucose levels ≥100 mg/dL, blood triglycerides ≥150 mg/dL, HDL cholesterol <50 mg/dL, 
or self-reported hypertension and/or hypertension medication use within one year of endometrial 
cancer diagnosis. The alternate hypertension criterion was used as direct blood pressure 
measurements were not available from the original case-control study [16,20]. Twenty-seven 
participants were missing one or more metabolic syndrome components (missing: waist 
circumference n = 4; fasting blood glucose levels n = 20; blood triglycerides n = 23; HDL 
cholesterol n = 20). Participants with partial missing metabolic syndrome data who still met three 
or more metabolic syndrome components criteria were classified as having metabolic syndrome 
(n = 7). 
 
Cox proportional hazards regression models were used to estimate multivariable-adjusted hazard 
ratios (HR) and 95% confidence intervals (95% CI) for the associations between metabolic 
syndrome (yes, no), the number of metabolic syndrome components (0–1, 2–3, 4–5) and 
individual metabolic syndrome components with disease-free survival, overall survival and 
recurrence outcomes. Fine and Gray competing risk models were used for the endometrial 
cancer-specific survival outcome. The individual metabolic syndrome components tested were: 
waist circumference (≥88 cm, per 5 cm), fasting blood glucose levels (≥100 mg/dL, per 
5 mg/dL), blood triglycerides (≥150 mg/dL, per 5 mg/dL), HDL cholesterol (<50 mg/dL, per 
5 mg/dL), and self-reported hypertension (yes, no). Continuous exposures were centred at 
dichotomous cut-points. All models were hierarchically well-formulated and adjusted for 
endometrial cancer stage (I, II, III/IV), grade (I/II, III, unknown/non-applicable), primary cancer 
treatment(s) (hysterectomy, hysterectomy/chemotherapy, hysterectomy/radiation, hysterectomy/ 
chemotherapy/radiation and/or hormone therapy, missing treatment), baseline age (years) and 
non-linear age (age2) based on a priori biological plausibility. Additionally, disease-free survival 
models were adjusted for the time to first new primary cancer, overall survival models were 
adjusted for the time to first recurrence/new primary cancer, and endometrial cancer-specific 
survival models were adjusted for the time to first recurrence. Moreover, all metabolic syndrome 
component models were mutually adjusted for the other metabolic syndrome risk factors. 
 
Additional confounding variables were identified via backwards elimination. Continuous BMI 
(kg/m2) was included in all multivariable-adjusted models while there was only evidence that the 
number of major comorbidities (0, 1, ≥2 of any of the following: angina pectoris, pulmonary 
embolism, myocardial infarction, stroke, thrombosis) confounded the association between 
metabolic syndrome with disease-free and overall survival. There was insufficient evidence that 
lifetime alcohol consumption (grams/year), marital status (married/common law, other), 
hormone replacement treatment status (ever, never), parity (null,1–2, ≥2) menopausal status (pre 
or peri-menopausal, post-menopausal), smoking pack years defined as: (number of cigarettes 
smoked daily)*(duration of smoking in years)/ 20, highest education attained (≤high school, non-
university certificate, university degree), residency (rural, urban) or first degree family history of 
uterine (NOS) or colorectal cancer (yes, no/missing) confounded the associations of interest. Nor 
was there evidence that fasting blood insulin levels (pM/ml) confound associations in fasting 
blood glucose models. 
 
Potential modification of the association between metabolic syndrome and its components with 
overall and disease-free survival by BMI (kg/m2) and lifetime recreational physical activity 
(metabolic-equivalent task [MET]-hours/week/year) were assessed with Wald-tests. Associations 
with statistically significant effect modification are presented by median groups. 
 
The proportional hazards assumption was evaluated with visual and statistical assessments of 
Schoenfeld residuals and Wald-tests for the interaction of the exposure variable and time in the 
Cox models and Fine and Gray models, respectively. Results are not presented for the analyses 
that did not satisfy the proportional hazards assumption. Sample size for this analysis was 
predetermined by the number of available cases; hence, the final analytical sample included 
participants with complete metabolic syndrome data (n = 520) and complete metabolic syndrome 
component data (n = 513; Fig. 1). All analyses were performed using Stata software version 15.1 
(StataCorp LLC. College Station, TX). 
 
 




Among the 540 endometrial cancer survivors, 325 (60.2%) had metabolic syndrome at the time 
of endometrial cancer diagnosis and 132 had a recurrence and/or died during the median 
14.2 years of follow-up (range: 0.3–16.5 years). Specifically, there were 73 recurrences, 50 
endometrial cancer-specific deaths and 111 overall deaths during follow-up. Most participants 
were diagnosed with endometroid histology (81.5%), low stage and grade endometrial cancer 
(Stage I: 77.8%; Grade I: 53.3%), had hysterectomy as part of primary treatment (97.6%) and a 
mean age of 59.1 (SD 9.3) years (Table 1). 
 
Table 1. Participant Characteristics of the Alberta Endometrial Cancer Cohort by Vital Status, 
Alberta, Canada (N = 540). 
Characteristics 
(Mean (SD); N (%)) 
All 
(n = 540) 
Alive 
(n = 429) 
Disease-Free 
Survival (n = 132) 
Overall Deaths 
(n = 111) 
Cancer-Specific 
Deaths (n = 50) 
Age at diagnosis (years) 59.1 (9.3) 57.6 (8.8) 63.5 (9.8) 64.9 (9.2) 62.7 (7.7) 
Highest Education 
     
High school diploma 177 (32.8) 134 (31.2) 50 (37.9) 43 (38.7) 15 (30.0) 
Non-university certificate 249 (46.1) 198 (46.2) 61 (46.2) 51 (46.0) 26 (52.0) 
University degree 114 (21.1) 97 (22.6) 21 (15.9) 17 (15.3) 9 (18.0) 
Married/common-law 372 (68.9) 300 (69.9) 84 (63.6) 72 (64.9) 30 (60.0) 
White 507 (93.9) 401 (93.5) 123 (93.2) 106 (95.5) 46 (92.0) 
Urban residence 363 (67.2) 300 (69.9) 77 (58.3) 63 (56.8) 32 (64.0) 
Parity 
     
0 111 (20.6) 91 (21.2) 23 (18.70) 20 (18.0) 8 (16.0) 
1–2 248 (45.9) 208 (48.5) 45 (36.59) 40 (36.0) 21 (42.0) 
>2 181 (33.5) 130 (30.3) 55 (44.72) 51 (46.0) 21 (42.0) 
Post-Menopausal 415 (76.9) 312 (72.7) 116 (87.9) 103 (92.8) 45 (90.0) 
Histology 
     
Endometroid 440 (81.5) 366 (85.3) 91 (68.9) 74 (66.7) 28 (56.0) 
Non-Endometroid 100 (18.5) 63 (14.7) 41 (31.1) 37 (33.3) 22 (44.0) 
Overall AJCC stage 
     
I 428 (79.3) 362 (84.4) 78 (59.1) 66 (59.5) 17 (34.0) 
II 69 (12.8) 49 (11.4) 25 (18.9) 20 (18.0) 11 (22.0) 
III/IV 43 (8.0) 18 (4.2) 29 (22.0) 25 (22.5) 22 (44.0) 
FIGO Grade 
     
I 288 (53.3) 250 (58.3) 47 (35.6) 38 (34.2) 10 (20.0) 
II 125 (23.2) 102 (23.8) 27 (20.5) 23 (20.7) 11 (22.0) 
III 73 (13.5) 41 (9.6) 36 (27.3) 32 (28.8) 18 (36.0) 
Not Reported/Missing 54 (10.0) 36 (8.4) 22 (16.7) 18 (12.2) 11 (22.0) 
Primary treatment 
     
Hysterectomy 527 (97.6) 422 (98.4) 120 (90.9) 105 (94.6) 46 (92.0) 
Chemotherapy 45 (8.3) 26 (6.1) 20 (15.2) 19 (17.1) 17 (34.0) 
Hormone therapy 6 (1.1) 6 (1.4) 2 (1.5) 0 (0) 0 (0) 
Radiation therapy 168 (31.1) 124 (28.9) 52 (39.4) 44 (39.6) 21 (42.0) 
Not Received 33 (6.1) 16 (3.7) 25 (18.9) 17 (15.3) 12 (24.0) 
New Primary Cancer 92 (17.0) 63 (14.7) 33 (25.0) 29 (26.1) 2 (4.0) 
Family History of Uterine or 
Colorectal Cancer 
88 (16.3) 64 (14.9) 27 (20.5) 24 (21.6) 12 (24.0) 
BMI (kg/m2) 32.3 (7.9) 32.1 (17.1) 33.2 (17.6) 33.0 (9.1) 33.3 (17.6) 
Smoker (Ever) 271 (50.2) 218 (50.8) 62 (47.0) 53 (47.8) 19 (38.0) 
Lifetime recreational PA 
(Mets-hours/week/year) 
12.1 (9.2) 12.5 (9.6) 11.2 (8.9) 10.5 (7.5) 10.6 (7.3) 
Metabolic Syndrome 325 (60.2) 248 (57.8) 87 (65.9) 77 (69.4) 37 (74.0) 
Metabolic Syndrome Components 
     
0–1 81 (15.0) 68 (15.9) 15 (11.4) 13 (11.7) 5 (10.0) 
2 114 (21.1) 98 (22.8) 23 (17.4) 16 (14.4) 6 (12.0) 
3 147 (27.2) 117 (27.3) 32 (24.2) 30 (27.0) 18 (36.0) 
4 130 (24.1) 95 (22.1) 41 (31.1) 35 (31.5) 14 (28.0) 
5 48 (8.9) 36 (8.4) 14 (10.6) 12 (10.8) 5 (10.0) 
Characteristics 
(Mean (SD); N (%)) 
All 
(n = 540) 
Alive 
(n = 429) 
Disease-Free 
Survival (n = 132) 
Overall Deaths 
(n = 111) 
Cancer-Specific 
Deaths (n = 50) 
Waist Circumference (cm) 98.0 (18.8) 97.4 (18.2) 100.6 (20.1) 100.5 (20.9) 99.1 (22.5) 
Fasting Glucose (mg/dL) 122.6 (43.4) 123.2 (44.1) 120.1 (38.7) 120.4 (40.4) 118.3 (38.5) 
Triglycerides (mg/dL) 146.8 (97.9) 143.8 (97.5) 161.6 (102.7) 158.2 (98.7) 154.6 (87.8) 
HDL Cholesterol (mg/dL) 37.3 (12.7) 37.9 (12.4) 34.9 (13.7) 35.2 (13.8) 36.3 (13.9) 
Hypertension (self-reported) 186 (34.4) 133 (31.0) 57 (43.2) 53 (47.8) 22 (44.0) 
AJCC: American Joint Committee on Cancer, FIGO: International Federation of Gynecology and Obstetrics, BMI: 
body mass index (kg/m2), PA: Physical Activity, HDL: High-Density Lipoprotein. 
Women with incomplete TMN stage (n = 8) were categorized as Stage I. 
 
In the multivariable-adjusted analyses, a statistically significant association between metabolic 
syndrome and worse overall survival (HR = 1.98, 95% CI = 1.07–3.67) was observed (Table 2). 
The association with metabolic syndrome and endometrial cancer-specific survival did not reach 
statistical significance (HR = 1.80, 95% CI = 0.75–4.33). Likewise, there was insufficient 
evidence of associations between metabolic syndrome with disease-free survival or endometrial 
cancer recurrence in these analyses (Table 2). 
 
Table 2. Disease-Free Survival, Overall Survival, Endometrial Cancer-Specific Survival and 
Recurrence Outcomes for Endometrial Cancer Survivors in the Alberta Endometrial Cancer 
Cohort, Alberta, Canada (N = 520).  
Disease-Free Survival 
(n = 125/520) 
Overall Survival 
(n = 106/520) 
Endometrial Cancer-
Specific Survival 
(n = 48/520) 
Recurrence 
















HR (95% CI) 
Metabolic Syndrome         
No 38/195 1.00 29/195 1.00 11/195 1.00 22/195 1.00 
Yes 87/325 1.05 (0.68–1.63) 77/325 1.98 (1.07–3.67) 37/325 1.80 (0.75–4.33) 47/325 0.77 (0.43–1.38) 
Waist Circumference (cm)         
<88 32/168 1.00 28/168 1.00 13/168 1.00 18/168 1.00 
≥88 90/345 1.66 (0.98–2.79) 75/345 2.12 (1.18–3.80) 34/345 2.14 (0.73–6.31) 50/345 1.21 (0.58–2.52) 
Per 5 cm increase  1.11 (1.00–1.24)  1.21 (1.07–1.36)  1.09 (0.91–1.31)  1.04 (0.90–1.21) 
Fasting Glucose (mg/dL)        
<100 44/177 1.00 38/177 1.00 17/177 1.00 25/177 1.00 
≥100 78/336 NR 65/336 NR 30/336 0.65 (0.33–1.31) 42/336 0.77 (0.46–1.30) 
Per 5 mg/dL increase 0.98 (0.95–1.00)  0.98 (0.96–1.01)  NR  0.98 (0.95–1.01) 
Triglycerides (mg/dL)        
<150 69/331 1.00 58/331 1.00 24/331 1.00 38/331 1.00 
≥150 53/182 1.35 (0.90–2.02) 45/182 1.32 (0.83–2.10) 23/182 1.26 (0.56–2.86) 30/182 1.08 (0.61–1.89) 
Per 5 mg/dL increase 1.01 (1.00–1.01)  1.00 (0.99–1.01)  1.00 (0.98–1.01)  1.00 (0.98–1.01) 
HDL Cholesterol (mg/dL)        
≥50 16/73 1.00 14/73 1.00 7/73 1.00 9/73 1.00 
<50 106/440 0.61 (0.34–1.08) 89/440 0.55 (0.29–1.03) 40/440 0.31 (0.12–0.82) 59/440 0.63 (0.29–1.34) 
Per 5 mg/dL increase 0.94 (0.87–1.02)  0.96 (0.88–1.04)  1.01 (0.85–1.21)  0.95 (0.85–1.06) 
Hypertension         
No 70/339 1.00 54/339 1.00 26/339 1.00 44/339 1.00 
Yes 52/174 0.90 (0.60–1.34) 49/174 1.18 (0.77–1.81) 21/174 1.01 (0.85–1.21) 24/174 0.55 (0.31–1.00) 
Hazard Ratios (HR), Confidence Interval (CI), Not Reported (NR), Components models (n = 513). 
 
Multivariable models adjusted for stage (I/missing, II, III/IV), grade (I/II, III, missing), primary 
treatment(s) (hysterectomy, hysterectomy/chemotherapy, hysterectomy/radiation, 
hysterectomy/chemotherapy/ radiation and/or hormone therapy, missing treatment), baseline age 
(years), non-linear age (age2) and continuous BMI (kg/m2). Disease-free survival model 
additionally adjusted for time to first new primary cancer; Overall survival additionally adjusted 
for time to first new primary cancer/recurrence; Endometrial cancer-specific survival 
additionally adjusted for time to first recurrence. 
 
All models for metabolic syndrome components were mutually adjusted for the other 
components. 
 
Disease-free survival and overall survival metabolic syndrome multivariable models were 
additionally adjusted for number of major comorbidities (0, 1, ≥2). 
 
For the individual components of metabolic syndrome, waist circumference (≥88 cm) was 
associated with statistically significantly worse overall survival (HR = 2.12, 95% CI = 1.18–
3.80) but not disease-free survival (HR = 1.66, 95% CI = 0.98–2.79), endometrial cancer-specific 
survival (HR = 2.14, 95% CI = 0.73–6.31) or recurrence (HR = 1.21, 95% CI = 0.58–2.52). 
Positive linear dose-response relationships were observed per 5 cm increase in waist 
circumference with overall survival (HRper 5 cm = 1.21, 95% CI = 1.07–1.36) and disease-free 
survival (HRper 5 cm = 1.11, 95% CI = 1.00–1.24) in the multivariable-adjusted models. 
 
Lifetime recreational physical activity prior to diagnosis (MET-hours/week/year) significantly 
modified (p-value<.05) the associations between metabolic syndrome, waist circumference (per 
5 cm), HDL cholesterol (per 5 mg/dL) and hypertension with overall survival as well as the 
association between HDL cholesterol (per 5 mg/dL) and disease-free survival in the 
multivariable-adjusted models. Specifically, among endometrial cancer survivors with lower 
lifetime recreational physical activity (<9.7 MET-hours/week/year), those with metabolic 
syndrome had worse overall survival (HR = 2.45, 95% CI = 1.19–5.05) compared to participants 
without the syndrome. No association with metabolic syndrome and overall survival was 
observed among survivors with higher recreational physical activity (for ≥9.7 MET-
hours/week/year, HR = 0.88, 95% CI = 0.46–1.69). Increasing waist circumference was 
associated with worse overall survival for women with lower (HRper 5 cm = 1.30, 95% CI = 1.13–
1.49), as well as higher (HRper 5 cm = 1.16, 95% CI = 1.02–1.32) lifetime recreational physical 
activity. Improved overall survival (HRper 5 mg/dL = 0.85, 95% CI = 0.76–0.96) and disease-free 
survival (HRper 5 mg/dL = 0.85, 95% CI = 0.76–0.94) was observed for greater HDL cholesterol 
levels (per 5 mg/dL) among women with lower physical activity. Lastly, hypertension was 
associated with worse overall survival (HR = 1.80, 95% CI = 1.02–3.18) among endometrial 
cancer survivors with lower lifetime recreational physical activity. 
 
Finally, the models assessing the number of metabolic syndrome components and fasting blood 
glucose did not satisfy the proportional hazard assumption and are therefore not reported. 
 
4. Discussion 
In the current study, endometrial cancer survivors with metabolic syndrome had approximately a 
two-fold decrease in overall survival compared to study participants who did not have this 
syndrome. Our findings also suggest that metabolic syndrome may be associated with worse 
endometrial cancer-specific survival although the association was not statistically significant in 
the multivariable-adjusted model. There was insufficient evidence of an association between 
metabolic syndrome and disease-free survival or endometrial cancer recurrence in the present 
study. Finally, of the individual metabolic syndrome components, only waist circumference was 
observed to be associated with survival outcomes. 
 
To our knowledge, this investigation is the first study among endometrial cancer survivors to use 
a standardized definition of metabolic syndrome to test its association with survival outcomes as 
well as the first conducted in a North American context. Our findings are generally consistent 
with prior literature that observed worse overall and endometrial cancer-specific survival with 
metabolic syndrome among endometrial cancer survivors. Ni and colleagues [28] used a study-
specific definition of metabolic syndrome (presence of ≥three of the following components: 
history of Type 2 diabetes, medically-treated hypertension, diagnosed or treated hyperlipidemia 
and either waist circumference ≥ 80 cm or BMI ≥28 kg/m2) to assess the association with all-
cause mortality among histologically confirmed endometrial cancer cases (n = 385; n = 64 
deaths) in China. The authors noted that endometrial cancer survivors with the study-specific 
metabolic syndrome had 6.65 (95% CI = 1.93, 47.79) times the hazard of all-cause mortality 
compared to those without metabolic syndrome [28]. The same study-specific metabolic 
syndrome definition used by Ni et al. [28], was also associated with worse overall survival 
among 139 Chinese non-endometrioid uterine cancer patients [29]. Within the Metabolic 
Syndrome and Cancer Project (Me-Can), metabolic syndrome was associated with 1.56 (95% 
CI = 1.32, 1.84) times the hazard of uterine cancer-specific mortality per one-unit increment of 
composite metabolic syndrome Z-score [30]. 
 
In the current study, women with a waist circumference above 88 cm had approximately half the 
overall survival compared to women with a waist circumference below 88 cm. Furthermore, for 
every additional 5 cm increase in waist circumference above 88 cm, women were estimated to 
have a 21% decrease in overall survival and an 11% decrease in disease-free survival. Our 
findings also suggest that greater waist circumference may also be associated with worse 
disease-free survival, endometrial cancer-specific survival and recurrence although these 
associations were attenuated by BMI. Previous research has shown that both waist circumference 
and BMI are positively correlated with estrogen levels in endometrial cancer survivors, 
unopposed estrogens released by adipose tissue is a known risk factor of endometrial cancer 
tumor proliferation [10,31]. The underlying mechanism of pathogenesis via adipose tissue and 
elevated estrogen concentrations may partially explain why the associations between waist 
circumference with disease-free survival, endometrial cancer-specific survival and recurrence 
were attenuated by BMI. However, waist circumference is a strong indicator of central adiposity 
which has been positively associated with additional biological mechanisms related to 
hyperglycemia, dyslipidemia, hyperinsulinemia and systemic inflammation that may also drive 
tumor pathogenesis [10]. Previous findings from the Nurses' Health Study observed that women 
had a 34% (95% CI = 23%–39%) increase in all-cause mortality and a 18% (95% CI = 9%–28%) 
increase in obesity-related (colon cancer, breast cancer, pancreatic cancer, uterine, ovarian, and 
kidney cancer) cancer mortality per ~10 cm increase in waist circumference in multivariable 
adjusted models including adjustments for BMI [32]. 
 
To our knowledge, the present study is the first to assess whether lifetime physical activity prior 
to diagnosis impacts the relationship between metabolic syndrome at diagnosis and its 
components with survival outcomes among endometrial cancer survivors. Our findings suggest 
that women with greater lifetime recreational physical activity participation do not experience 
the same harmful associations between metabolic syndrome, waist circumference, and 
hypertension with overall survival compared to those with lower amounts of lifetime physical 
activity participation. A protective association was also observed with increasing HDL 
cholesterol and survival outcomes among women with lower lifetime physical activity 
participation. These findings add to current literature that suggests cancer survivors with greater 
physical activity participation experience better survival, although specific estimates among 
endometrial cancer survivors are limited [33,34]. Arem and colleagues previously reported an 
association between pre-diagnosis recreational moderate-to-vigorous-intensity physical activity 
and lower overall 5-year mortality, but not 10-year mortality, endometrial cancer-specific 
mortality or all-cause mortality in the Women's Health Initiative [35] and the National Institutes 
of Health- American Association of Retired Persons (NIH–AARP) Diet and Health Study [36]. 
 
This study has several key strengths, including a substantial study follow-up time of nearly 
17 years. Participants were representative of the larger endometrial cancer survivor population 
living in Alberta since cases were originally identified through the Alberta Cancer Registry 
which has a ≥ 95% case ascertainment rate [37] of histologically confirmed, endometrial cancer 
cases. Additionally, data linkage with national and provincial registries ensured that 
comprehensive vital status data were captured. Direct measurements of most of the metabolic 
syndrome components, particularly the anthropometric measures and blood assays, were 
assessed in multiple to provide valid and reliable data. Finally, covariates were extensively 
measured during the in-person interviews and interviewers were trained with cognitive interview 
methods. 
 
Some limitations must be acknowledged in the current study. Primarily, the small sample size 
and limited number of events may have hindered the ability of the current study to observe 
statistically significant associations. Particularly the estimates of endometrial cancer-specific 
survival and recurrence should be interpreted with caution because of the small number of events 
in the dichotomized analyses. Larger studies are thus needed to confirm and contribute to our 
findings. Moreover, some results could not be presented because the proportional hazard 
assumptions were violated. The metabolic syndrome was only assessed at the time of cancer 
diagnosis and may not represent an individual's health status for the entire follow-up period. 
Consequently, the prevalence of metabolic syndrome may have been underestimated in this 
cohort. However, previous findings from the Atherosclerosis Risk in Communities Study suggest 
that, for the majority of individuals (76%), the severity of metabolic syndrome increases over 
time [38]. Moreover, medical treatment of individual risk factors failed to reduce the severity of 
metabolic syndrome during the follow-up period in the Atherosclerosis Risk in Communities 
Study [38]. Therefore, women in the current study likely did not have improved metabolic heath 
status during follow-up if they had metabolic syndrome or some of its components at baseline. 
Finally, given that the study participants represent a largely homogenous group of White 
(93.9%), well educated (67.2% ≥ high school education), endometrial cancer survivors living in 
Alberta, the current findings may not be generalizable to all populations including racial-ethnic 
minority populations in Canada. 
 
Given that endometrial cancer mortality rates are currently rising [3,4] and women living with 
endometrial cancer have greater amounts of diagnosed, undiagnosed or undertreated 
cardiometabolic risk factors compared to the general population [39], identifying opportunities to 
intervene is becoming increasingly important. In this study, the results suggest that the 
association between metabolic syndrome and endometrial cancer survival is largely explained by 
central adiposity. Moreover, endometrial cancer survivors with greater lifetime recreational 
physical activity had improved survival despite metabolic syndrome risk factors compared to 
those with lower lifetime physical activity. Additional research is needed to confirm these results 
and improve our understanding of the role of physical activity and other lifestyle factors in 
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